Pharmacokinetics of ganciclovir in renal transplant children.
Three cytomegalovirus (CMV)-seronegative children received renal transplants from CMV-seropositive donors and developed clinical symptoms of CMV infection between days 20 and 34 post transplantation. Ganciclovir (DHPG) was administered in a 1-h infusion, and the doses and dose intervals were adapted to the degree of renal insufficiency, according to the manufacturer's recommendations for adults. Individual pharmacokinetic parameters of DHPG were determined and were markedly altered. Plasma clearances were 0.4, 1.1 and 2.2 ml/min per kg and were related to individual creatinine clearances (20, 45 and 60 ml/min per 1.73 m2); the corresponding elimination half-lives were 23.7, 9.9 and 3.9 h. In two patients, the doses had to be further reduced in order to maintain plasma levels within the recommended values for peak and trough plasma concentrations. Therefore, monitoring of DHPG appears essential in adjusting dosage for optimal efficacy and minimal toxicity.
Jacqz-Aigrain
E
E
Department of Clinical Pharmacology, Hôpital Robert-Debré, Pairs, France.
Macher
M A
MA
Sauvageon-Marthe
H
H
Brun
P
P
Loirat
C
C
D000293:Adolescent; D002648:Child; D003586:Cytomegalovirus Infections / Q000209:etiology / Q000378:metabolism*; D005260:Female; D015774:Ganciclovir / Q000008:administration & dosage / Q000493:pharmacokinetics*; D006801:Humans; D007262:Infusions, Intravenous; D007668:Kidney / Q000378:metabolism; D016030:Kidney Transplantation / Q000009:adverse effects; D008297:Male; D014766:Viremia / Q000378:metabolism
D015774:Ganciclovir